[
  {
    "ts": null,
    "headline": "Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again",
    "summary": "Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=ea281caba7786c41b683de52b3cf9d31e001f1176a9f8ee485aa630a4c239dbc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760026203,
      "headline": "Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again",
      "id": 137033571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=ea281caba7786c41b683de52b3cf9d31e001f1176a9f8ee485aa630a4c239dbc"
    }
  },
  {
    "ts": null,
    "headline": "Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=4b0ae99242c8395a57369dcebdee22e290e95ad187d78d50c3334187eb7b1e7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760017501,
      "headline": "Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term",
      "id": 137033572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=4b0ae99242c8395a57369dcebdee22e290e95ad187d78d50c3334187eb7b1e7e"
    }
  },
  {
    "ts": null,
    "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=3fbd195c73a91db415c2ff338e8ec041fd8e1dea47d09417c3de398e2c8949b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760014804,
      "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
      "id": 137033444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=3fbd195c73a91db415c2ff338e8ec041fd8e1dea47d09417c3de398e2c8949b3"
    }
  },
  {
    "ts": null,
    "headline": "IDEXX Laboratories (IDXX): Exploring Valuation After Impressive Share Price Momentum",
    "summary": "IDEXX Laboratories (IDXX) has delivered a solid stretch for shareholders lately, keeping many investors tuned into its recent performance. The company’s share price has moved steadily in recent months and offers an interesting case for healthcare stock watchers. See our latest analysis for IDEXX Laboratories. Momentum has picked up for IDEXX Laboratories this year, with the share price now at $629.91 and a remarkable year-to-date price return of 54.07%. Over the past 12 months, long-term...",
    "url": "https://finnhub.io/api/news?id=cdd6db8c1ec190201219e6aea16a5ebe55720eb7736348cdae1a9419a574d7b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759979353,
      "headline": "IDEXX Laboratories (IDXX): Exploring Valuation After Impressive Share Price Momentum",
      "id": 137028472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "IDEXX Laboratories (IDXX) has delivered a solid stretch for shareholders lately, keeping many investors tuned into its recent performance. The company’s share price has moved steadily in recent months and offers an interesting case for healthcare stock watchers. See our latest analysis for IDEXX Laboratories. Momentum has picked up for IDEXX Laboratories this year, with the share price now at $629.91 and a remarkable year-to-date price return of 54.07%. Over the past 12 months, long-term...",
      "url": "https://finnhub.io/api/news?id=cdd6db8c1ec190201219e6aea16a5ebe55720eb7736348cdae1a9419a574d7b1"
    }
  },
  {
    "ts": null,
    "headline": "Should Investors Reevaluate IDEXX After Its 54% 2025 Share Price Surge?",
    "summary": "If you’re wondering what to make of IDEXX Laboratories right now, you’re not alone. The stock continues to make headlines, and investors weighing whether to buy, hold, or cash out are facing a familiar crossroads. Over the past year, the share price has leapt by 32.7%, with an even more impressive 54.1% surge from the start of the year. The last seven days even brought a modest bump of 1.6%, adding a little more momentum. However, a 3.5% dip over the last month suggests it hasn’t all been...",
    "url": "https://finnhub.io/api/news?id=10f488f369c9b9389069213a0d3b4b3e25f82f47507e95f83a500d646ecb5536",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759972381,
      "headline": "Should Investors Reevaluate IDEXX After Its 54% 2025 Share Price Surge?",
      "id": 137028473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IDXX",
      "source": "Yahoo",
      "summary": "If you’re wondering what to make of IDEXX Laboratories right now, you’re not alone. The stock continues to make headlines, and investors weighing whether to buy, hold, or cash out are facing a familiar crossroads. Over the past year, the share price has leapt by 32.7%, with an even more impressive 54.1% surge from the start of the year. The last seven days even brought a modest bump of 1.6%, adding a little more momentum. However, a 3.5% dip over the last month suggests it hasn’t all been...",
      "url": "https://finnhub.io/api/news?id=10f488f369c9b9389069213a0d3b4b3e25f82f47507e95f83a500d646ecb5536"
    }
  }
]